Identification

Name
Triflupromazine
Accession Number
DB00508  (APRD00465)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem]

Structure
Thumb
Synonyms
  • 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine
  • 2-(Trifluoromethyl)promazine
  • 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine
  • Fluopromazine
  • Triflupromazin
  • Triflupromazina
  • Triflupromazine
  • Triflupromazinum
External IDs
MC 4703 / SKF 4648-A
Product Ingredients
IngredientUNIICASInChI Key
Triflupromazine Hydrochloride9E75N4A5HM1098-60-8FTNWXGFYRHWUKG-UHFFFAOYSA-N
International/Other Brands
Vesprin (Bristol Myers Squibb)
Categories
UNII
RO16TQF95Y
CAS number
146-54-3
Weight
Average: 352.417
Monoisotopic: 352.122103923
Chemical Formula
C18H19F3N2S
InChI Key
XSCGXQMFQXDFCW-UHFFFAOYSA-N
InChI
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
dimethyl({3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl})amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F

Pharmacology

Indication

Used mainly in the management of psychoses. Also used to control nausea and vomiting.

Structured Indications
Not Available
Pharmacodynamics

Triflupromazine is a member of a class of drugs called phenthiazines, which are dopamine D1/D2 receptor antagonists. Phenothiazines are used to treat serious mental and emotional disorders, including schizophrenia and other psychotic disorders. It reduces anxiety, emotional withdrawal, hallucinations, disorganized thoughts, blunted mood, and suspiciousness. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system.

Mechanism of action

Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B).

TargetActionsOrganism
AD(1A) dopamine receptor
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2B
antagonist
Human
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption

Absorption may be erratic and peak plasma concentrations show large interindividual differences.

Volume of distribution
Not Available
Protein binding

Very high (90% or more).

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineTriflupromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTriflupromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Triflupromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with 7-Nitroindazole.Experimental
AcebutololTriflupromazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Triflupromazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triflupromazine.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Allopregnanolone.Investigational
AlmagateAlmagate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Triflupromazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triflupromazine.Approved, Illicit, Investigational
AlprenololTriflupromazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Triflupromazine.Approved, Illicit
AmodiaquineThe serum concentration of Triflupromazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amperozide.Experimental
AmphetamineTriflupromazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triflupromazine.Approved, Investigational
ArotinololTriflupromazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ArtemetherThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Triflupromazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Triflupromazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Triflupromazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Triflupromazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Triflupromazine.Approved
AtenololTriflupromazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Triflupromazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azaperone.Investigational, Vet Approved
AzelastineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.Illicit
BefunololTriflupromazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzocaine.Approved
BenzphetamineTriflupromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzyl alcohol.Approved
BetaxololTriflupromazine may increase the hypotensive activities of Betaxolol.Approved
BevantololTriflupromazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideTriflupromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololTriflupromazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololTriflupromazine may increase the hypotensive activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Triflupromazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Triflupromazine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triflupromazine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololTriflupromazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolTriflupromazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triflupromazine.Approved, Investigational
BupranololTriflupromazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triflupromazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Triflupromazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triflupromazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carisoprodol.Approved
CarteololTriflupromazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolTriflupromazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololTriflupromazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triflupromazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorphenamine.Approved
ChlorphentermineTriflupromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Triflupromazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triflupromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clopenthixol.Experimental
CloranololTriflupromazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triflupromazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Triflupromazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triflupromazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Triflupromazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.Approved
Cycloguanil embonateThe serum concentration of Triflupromazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Triflupromazine can be increased when it is combined with Dapsone.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Triflupromazine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineTriflupromazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Triflupromazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triflupromazine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Diethyl ether.Experimental
DiethylpropionTriflupromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triflupromazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triflupromazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triflupromazine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Triflupromazine.Approved, Investigational
DoxycyclineThe serum concentration of Triflupromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Triflupromazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Triflupromazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Triflupromazine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triflupromazine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Entacapone.Approved, Investigational
EpanololTriflupromazine may increase the hypotensive activities of Epanolol.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Triflupromazine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.Approved, Investigational
EsmololTriflupromazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Triflupromazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triflupromazine.Approved
EthanolTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triflupromazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triflupromazine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triflupromazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Triflupromazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Triflupromazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Triflupromazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Triflupromazine.Approved, Illicit, Investigational
GepefrineTriflupromazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Triflupromazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triflupromazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hexobarbital.Approved
HydrocodoneTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineTriflupromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.Investigational, Withdrawn
IndenololTriflupromazine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indiplon.Investigational
Iofetamine I-123Triflupromazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triflupromazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Triflupromazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triflupromazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketobemidone.Approved, Investigational
LabetalolTriflupromazine may increase the hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lamotrigine.Approved, Investigational
LandiololTriflupromazine may increase the hypotensive activities of Landiolol.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Triflupromazine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levetiracetam.Approved, Investigational
LevobunololTriflupromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triflupromazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triflupromazine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Triflupromazine.Approved, Investigational
LisdexamfetamineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Triflupromazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triflupromazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Triflupromazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triflupromazine.Approved
LumefantrineThe serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triflupromazine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Triflupromazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melperone.Approved, Investigational
MephedroneTriflupromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTriflupromazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololTriflupromazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Meptazinol.Experimental
MequitazineTriflupromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTriflupromazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triflupromazine.Approved
MethotrimeprazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineTriflupromazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenobarbital.Approved
MetipranololTriflupromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.Approved, Investigational
MetoprololTriflupromazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineTriflupromazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triflupromazine.Approved, Illicit
MidomafetamineTriflupromazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Investigational
MirtazapineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Triflupromazine can be increased when it is combined with Mizoribine.Investigational
MMDATriflupromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triflupromazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Investigational
NadololTriflupromazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triflupromazine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Triflupromazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Triflupromazine.Approved, Investigational
NebivololTriflupromazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.Approved, Withdrawn
NicomorphineTriflupromazine may increase the hypotensive activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triflupromazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Triflupromazine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Opium.Approved, Illicit
OrphenadrineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triflupromazine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triflupromazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triflupromazine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triflupromazine.Approved
ParaldehydeTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.Approved
PenbutololTriflupromazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triflupromazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triflupromazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triflupromazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triflupromazine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenoxyethanol.Approved
PhentermineTriflupromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Triflupromazine.Approved
PindololTriflupromazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pizotifen.Approved
Platelet Activating FactorTriflupromazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pomalidomide.Approved
PractololTriflupromazine may increase the hypotensive activities of Practolol.Approved
PramipexoleTriflupromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triflupromazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Triflupromazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Triflupromazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.Approved, Vet Approved
ProguanilThe serum concentration of Triflupromazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Triflupromazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propoxycaine.Approved
PropranololTriflupromazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Triflupromazine.Approved
PSD502The risk or severity of adverse effects can be increased when Triflupromazine is combined with PSD502.Investigational
PseudoephedrineTriflupromazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Triflupromazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Triflupromazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Triflupromazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triflupromazine.Approved
QuinacrineThe serum concentration of Triflupromazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Triflupromazine.Approved
QuinidineThe serum concentration of Triflupromazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Triflupromazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Triflupromazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Triflupromazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triflupromazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triflupromazine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Triflupromazine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ritanserin.Investigational
RitobegronTriflupromazine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Triflupromazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Romifidine.Vet Approved
RopiniroleTriflupromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine.Approved
RotigotineTriflupromazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triflupromazine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Triflupromazine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Triflupromazine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.Approved
SinefunginThe serum concentration of Triflupromazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
SotalolTriflupromazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triflupromazine.Approved, Investigational
SulfadoxineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Triflupromazine.Approved, Investigational
SuvorexantTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Triflupromazine can be increased when it is combined with tafenoquine.Investigational
TalinololTriflupromazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Triflupromazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triflupromazine.Approved
TertatololTriflupromazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrodotoxin.Investigational
ThalidomideTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Triflupromazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triflupromazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tilidine.Experimental
TimololTriflupromazine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Triflupromazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Triflupromazine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triflupromazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trifluperidol.Experimental
TrimethoprimThe serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triprolidine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triflupromazine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Triflupromazine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vilazodone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Triflupromazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Triflupromazine.Approved, Investigational
ZolpidemTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Triflupromazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triflupromazine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14650
KEGG Drug
D00390
PubChem Compound
5568
PubChem Substance
46507344
ChemSpider
5367
BindingDB
67544
ChEBI
9711
ChEMBL
CHEMBL570
Therapeutic Targets Database
DAP000294
PharmGKB
PA451773
IUPHAR
4330
Guide to Pharmacology
GtP Drug Page
Wikipedia
Triflupromazine
ATC Codes
N05AA05 — Triflupromazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP5.54BIOBYTE (1995)
logS-5.3ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0018 mg/mLALOGPS
logP4.95ALOGPS
logP4.81ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.93 m3·mol-1ChemAxon
Polarizability35.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9839
Caco-2 permeable+0.7847
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8737
Renal organic cation transporterInhibitor0.6721
CYP450 2C9 substrateNon-substrate0.7813
CYP450 2D6 substrateSubstrate0.5115
CYP450 3A4 substrateSubstrate0.5822
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9141
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.8156
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6166
Ames testNon AMES toxic0.875
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.2485 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Inhibitor0.8433
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.91 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9013000000-ef47630a3d0764a3497f
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-3019000000-dc3f041820258623fda5
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9121000000-0dfbd5aaf88b987dbe84
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, organofluorine compound, tertiary amine (CHEBI:9711)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Cooper M, Wyllie JH: Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. [PubMed:497523]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:39